Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | KHK | P50053 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23513596 | 0.90 | HRH3 (0.40) | HRH3FFAR4CYP2D6MAPTLMNA | |
| SCHEMBL14725145 | 0.89 | HRH3 (0.54) | HRH3FFAR4CYP2D6MAPTKMT2A | |
| SCHEMBL20796091 | 0.77 | HRH3 (0.44) | HRH3FFAR4 | |
| SCHEMBL23513771 | 0.77 | HRH3 (0.37) | HRH3FFAR4KHKMAPTKMT2A | |
| SCHEMBL22102133 | 0.75 | HRH3 (0.43) | HRH3FFAR4CYP2D6 | |
| SCHEMBL14725158 | 0.75 | HRH3 (0.54) | HRH3CYP2D6LMNAHPGD | |
| SCHEMBL30803182 | 0.74 | CYP2C19 (0.37) | HRH3KHKCYP2D6HPGD | |
| SCHEMBL16984291 | 0.74 | HRH3 (0.35) | HRH3CYP2D6 | |
| SCHEMBL23513600 | 0.73 | GRM2 (0.34) | HRH3KHKCYP2D6KMT2ALMNA | |
| SCHEMBL21645635 | 0.72 | HRH3 (0.45) | HRH3FFAR4MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | Jubilant Prodel LLC | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | PDCD1, CD274, PDCD1LG2 | HRH3 2463/4885FFAR4 3558/4885KHK 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.